Abstract:BackgroundDegenerative diseases are a major public health concern for the aging population and mesenchymal stem cells (MSCs) have great potential for treating many of these diseases. However, the quantity and quality of MSCs declines with aging, limiting the potential efficacy of autologous MSCs for treating the elderly population.MethodsHuman bone marrow (BM)-derived MSCs from young and elderly donors were obtained and characterized using standard cell surface marker criteria (CD73, CD90, CD105) as recommended by the International Society for Cellular Therapy (ISCT). The elderly MSC population was isolated into four subpopulations based on size and stage-specific embryonic antigen-4 (SSEA-4) expression using fluorescence-activated cell sorting (FACS), and subpopulations were compared to the unfractionated young and elderly MSCs using assays that evaluate MSC proliferation, quality, morphology, intracellular reactive oxygen species, β-galactosidase expression, and adenosine triphosphate (ATP) content.ResultsThe ISCT-recommended cell surface markers failed to detect any differences between young and elderly MSCs. Here, we report that elderly MSCs were larger in size and displayed substantially higher concentrations of intracellular reactive oxygen species and β-galactosidase expression and lower amounts of ATP and SSEA-4 expression. Based on these findings, cell size and SSEA-4 expression were used to separate the elderly MSCs into four subpopulations by FACS. The original populations (young and elderly MSCs), as well as the four subpopulations, were then characterized before and after culture on tissue culture plastic and BM-derived extracellular matrix (BM-ECM). The small SSEA-4-positive subpopulation representing ~ 8% of the original elderly MSC population exhibited a “youthful” phenotype that was similar to that of young MSCs. The biological activity of this elderly subpopulation was inhibited by senescence-associated factors produced by the unfractionated parent population. After these “youthful” cells were isolated and expanded (three passages) on a “young microenvironment” (i.e., BM-ECM produced by BM cells from young donors), the number of cells increased ≈ 17,000-fold to 3 × 109 cells and retained their “youthful” phenotype.ConclusionsThese results suggest that it is feasible to obtain large numbers of high-quality autologous MSCs from the elderly population and establish personal stem cell banks that will allow serial infusions of “rejuvenated” MSCs for treating age-related diseases.

Age-related decreases of serum-response factor levels in human mesenchymal stem cells are involved in skeletal muscle differentiation and engraftment capacity

Age-related Changes in Bone Marrow Mesenchymal Stromal Cells

Myogenic differentiation potential of human tonsil-derived mesenchymal stem cells and their potential for use to promote skeletal muscle regeneration

Ex Vivo Expansion and Pluripotential Differentiation of Cryopreserved Human Bone Marrow Mesenchymal Stem Cells

Tissue‐specific functions of MSCs are linked to homeostatic muscle maintenance and alter with aging

Mesenchymal stem cell differentiation and roles in regenerative medicine.

Functional and Molecular Changes of Mscs in Aging

Biomechanical analysis predicts decreased human mesenchymal stem cell function before molecular differences

Analysis of Hub Genes Involved in Distinction Between Aged and Fetal Bone Marrow Mesenchymal Stem Cells by Robust Rank Aggregation and Multiple Functional Annotation Methods

Clinical-grade human umbilical cord-derived mesenchymal stem cells improved skeletal muscle dysfunction in age-associated sarcopenia mice

Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous Differentiation.

Aging alters tissue resident mesenchymal stem cell properties

Age-related changes in human bone marrow mesenchymal stromal cells: morphology, gene expression profile, immunomodulatory activity and miRNA expression

Aging of the skeletal muscle extracellular matrix drives a stem cell fibrogenic conversion

Rescuing Replication and Osteogenesis of Aged Mesenchymal Stem Cells by Exposure to a Young Extracellular Matrix.

Mesenchymal Stem Cell Aging: Mechanisms and Influences on Skeletal and Non-Skeletal Tissues

Restoring the quantity and quality of elderly human mesenchymal stem cells for autologous cell-based therapies

Impact of Donor Age on the Osteogenic Supportive Capacity of Mesenchymal Stromal Cell-Derived Extracellular Matrix

Embryonic-like Stem Cell Derived from Adult Bone Marrow: Immature Morphology, Cell Surface Markers, Ultramicrostructure and Differentiation into Multinucleated Fibers in Vitro.

Stem Cell Aging in Skeletal Muscle Regeneration and Disease

Anti-inflammatory therapeutic biomarkers identified of human bone marrow mesenchymal stem cell therapy on aging mice by serum proteomics and peptidomics study